Alisertib, an AURKB inhibitor, is also a synthetic lethal inhibitor in combination with paclitaxel that interferes with microtubules in mitosis and detected in NSCLC [130], breast and ovarian cancer [131] in phase II studies. This evidence concerns the gene AURKB and non-small cell lung carcinoma.